Icahn Enterprises IEP Pharma — Accounts Payable And Accrued Liabilities Current And Noncurrent
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — accounts payable and accrued liabilities current and noncurrent.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — accounts payable and accrued liabilities current and noncurrent?
- Icahn Enterprises (IEP) reported pharma — accounts payable and accrued liabilities current and noncurrent of $61M in Q1 2026.
- How has Icahn Enterprises's pharma — accounts payable and accrued liabilities current and noncurrent changed year-over-year?
- Icahn Enterprises's pharma — accounts payable and accrued liabilities current and noncurrent increased by 3.4% year-over-year, from $59M to $61M.
- What is the long-term trend for Icahn Enterprises's pharma — accounts payable and accrued liabilities current and noncurrent?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — accounts payable and accrued liabilities current and noncurrent has grown at a 5.2% compound annual growth rate (CAGR), from $202M to $247M.
- What does pharma — accounts payable and accrued liabilities current and noncurrent mean?
- The aggregate of short-term and long-term obligations owed to suppliers, vendors, and service providers related to pharmaceutical operations. This metric reflects the segment's reliance on trade credit and its ability to manage operational liabilities. Monitoring this helps evaluate working capital efficiency and supplier relationships.